Contribute Information
Can you contribute information about this project?
Contact the EWS Team
According to the Bank’s website, the project will finance the promoter's Research & Development (R&D;) to further develop transformative vascular implants using supramolecular chemistry. The R&D; investments focus on solutions for vascular access, coronary and peripheral bypass grafts, and pulmonary heart valves.
The project focuses on the development, clinical validation, and regulatory approval of aXess, an innovative haemodialysis conduit leveraging Xeltis' proprietary Endogenous Tissue Restoration (ETR) technology, which enables the body to naturally restore functional vascular tissue. Additionally, the concerned R&D; investments include clinical research, for novel therapeutic applications such as Coronary Artery Bypass Graft (XABG program), Peripheral Artery Diseases (Xpad program) and Pulmonary Valve (Xplore program).
According to the Environmental and Social Data Sheet, based on the environment, climate and social (ECS) information, the review of the ECS risks and impacts and the management systems in place, the project is deemed to have non-significant ECS risks impacts.
Xeltis BV is a Netherlands based clinical-stage medical device company pioneering a restorative approach in cardiovascular therapy.
| Private Actor 1 | Private Actor 1 Role | Private Actor 1 Sector | Relation | Private Actor 2 | Private Actor 2 Role | Private Actor 2 Sector |
|---|---|---|---|---|---|---|
| - | - | - | - | Xeltis BV | Client | - |
No contacts available at the time of disclosure.
ACCESS TO INFORMATION
You can submit an information request for project information at: https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm
ACCOUNTABILITY MECHANISM OF EIB
The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: http://www.eib.org/complaints/form via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf
When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces
